Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,127.3
4.7 (0.15%)

 

  • STI Straits Times Index
    3,127.3
    4.7 (0.15%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,600.6
    6.0 (0.38%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    26,049.4
    -220.6 (-0.84%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,883.4
    3.1 (0.11%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    20,628.0
    9.4 (0.05%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,246.2
    -6.8 (-0.11%)
    Index delayed 10 minutes
  • KOR KOSPI
    1,951.0
    -13.6 (-0.69%)
    Index delayed 20 minutes
  • XAO XAO
    6,593.0
    20.4 (0.31%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 642.8M
  • Value: 635.3M
  • Rise: 124
  • Fall: 153
  • Unch: 558

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
LionGold0.001-
ThaiBev0.940+0.015
YZJ Shipbldg SGD0.935-0.030
SingTel3.250+0.060
Kep Infra Tr0.510-
Rex Intl0.076-0.001
Koh Eco0.053+0.002
RHT HealthTrust0.018-
Jadason^0.037+0.002
Frasers L&I Tr1.180-0.040

World Indices

World Indices
Name Last Change
Nasdaq 8,020.2 +71.7
HSI 26,044.6 -225.5
HSCEI 10,131.1 -46.2
Jakarta 6,246.0 -7.0
Nikkei 225 20,628.0 +9.4
SSE Comp 2,883.4 +3.1
Shanghai A 3,020.7 +3.3
Shanghai B 264.3 -0.5
PSE Comp 0.0
KOSPI 1,951.0 -13.6

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

Suntar Eco-City^ SUNTAR ECO-CITY LIMITED
Quotes 10 Minutes Delayed. Updated at 22 Aug 2019 15:27
Last (SGD): 0.290 Change: - High: 0.290 Remarks: -
Change (%): - Low: 0.290
Open 0.290 Yesterday's Close 0.290
Buy Price 0.290 Sell Price -
Buy Volume ('000) 16.0 Sell Volume ('000) -
Cumulative Volume ('000) 4.0 Cumulative Value 1,160
Click to show Stock Prices chart

Key Statistics

EPS (SGD) a -0.04265 Trailing EPS (SGD) e -0.04914 NAV (SGD) b 0.2641
PE a - Trailing PE f - Price / NAV b 1.0981
Dividend (SGD) d - Cash In Hand (SGD) g 0.0135 Issued & Paid-up Shares c 62,760,000
Dividend Yield (%) d - Price / Cash In Hand g 21.481 Treasury Shares h -
Beta - 75 Daysi -2.466 R-Squared - 75 Days(%)i 1.32 Market Cap (M) 18.200
Beta - 500 Daysi -0.439 R-Squared - 500 Days (%)i 0.26 Enterprise Value (M) 3.758
Piotroski F Score 4 Exchange Code BKZ Par Value ( SGD ) n.a.
52 Weeks Volatility (%) 132.4828 6-Month VWAP 0.200 Free Float (%) -
Under CPF Investment Scheme (CPFIS) No
Sector & Industry Financial and Insurance Activities - Biotechnology
Category Classification China / Medical & Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 20 Aug 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand.
  9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference Suntar Eco-City^ SGX 18.200 - - 1.0981 -
Industry Biotechnology SGX 1,988.198 7.342 9.737 0.6940 4.744
China SGX 643.602 17.223 32.174 0.7671 3.593
Medical & Biotechnology SGX 1,025.987 23.494 26.833 1.4306 1.819
Local Peer Lonza SGX 5,937.453 7.663 9.330 0.6935 4.766
Local Peer QT Vascular SGX 8.941 0.222 - 0.5263 -
Global Peer AMGEN INC NASDAQ 122,303.022 14.570 15.369 11.3306 2.718
Global Peer GILEAD SCIENCES INC NASDAQ 81,217.439 14.889 13.639 3.5911 3.599
Global Peer AMGEN-T HKEx 599,701.000 9.116 9.612 7.1115 4.345
Global Peer CSL ASX 106,623.607 39.742 39.742 14.2485 1.138
Global Peer CELGENE CORP NASDAQ 67,812.339 16.760 12.865 6.7468 -
Global Peer VERTEX PHARMACEUTICAL NASDAQ 47,911.324 22.854 21.631 9.4500 -
Global Peer BIOGEN INC NASDAQ 43,009.351 9.707 8.124 3.3204 -
Global Peer ILLUMINA INC NASDAQ 42,703.500 51.699 45.526 9.8577 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 32,724.340 13.387 15.815 3.3543 -
Global Peer ALEXION PHARMACEUTICAL INC NASDAQ 25,750.229 331.831 19.309 2.5336 -
Other Global Peers AGILENT TECHNOLOGIES INC (NYSE), INCYTE CORPORATION (NASDAQ), SINO BIOPHARM (HKEx), EXACT SCIENCES CORP (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), SEATTLE GENETICS INC (NASDAQ), WUXI BIO (HKEx), IONIS PHARMACEUTICALS INC (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), BEIGENE (HKEx), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), BLUEBIRD BIO INC (NASDAQ), EXELIXIS INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), REPLIGEN CORP (NASDAQ), MODERNA INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), GENSCRIPT BIO (HKEx), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), 3SBIO (HKEx), BLUEPRINT MEDICINES CORP (NASDAQ), FIBROGEN INC (NASDAQ), SPARK THERAPEUTICS INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), ALKERMES PLC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), TILRAY INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), GENOMIC HEALTH INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), IMMUNOMEDICS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), XENCOR INC (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), NATERA INC (NASDAQ), UNIQURE N.V. (NASDAQ), MYRIAD GENETICS INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), AUDENTES THERAPEUTICS INC (NASDAQ), INSMED INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), REGENXBIO INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), VERACYTE INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), OPKO HEALTH INC (NASDAQ), EPIZYME INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), ALECTOR INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), INTREXON CORP (NASDAQ), OMEROS CORP (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), FRONTAGE (HKEx), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), CYTOKINETICS INC (NASDAQ), ARVINAS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), VIVA BIOTECH (HKEx), HOMOLOGY MEDICINES INC (NASDAQ), ALDER BIOPHARMACEUTICALS INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), MACROGENICS INC (NASDAQ), HAOHAI BIOTEC (HKEx), RHYTHM PHARMACEUTICALS INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), RETROPHIN INC (NASDAQ), POLYNOVO LIMITED (ASX), MYOVANT SCIENCES LTD (NYSE), MORPHIC HOLDING INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), UROGEN PHARMA LTD (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), NEXTCURE INC (NASDAQ), CORTEXYME INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), AVROBIO INC (NASDAQ), PERSONALIS INC (NASDAQ), SYNTHORX INC (NASDAQ), ASCLETIS-B (HKEx), ROCKET PHARMACEUTICALS INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), AVITA MEDICAL LTD (ASX), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), DERMIRA INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), MESOBLAST LTD (ASX), PRECISION BIOSCIENCES INC (NASDAQ), CKLIFE SCIENCES (HKEx), SYROS PHARMACEUTICALS INC (NASDAQ), SINOVAC BIOTECH (NASDAQ), KODIAK SCIENCES INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), MERUS B V (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), IMMUNOGEN INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), AGENUS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), MEDICINOVA INC (NASDAQ), RESTORBIO INC (NASDAQ), ESSEX BIO-TECH (HKEx), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), NEXT SCIENCE LTD (ASX), KADMON HLDGS INC (NYSE), REPLIMUNE GROUP INC (NASDAQ), XBIOTECH INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), STARPHARMA HOLDINGS LIMITED (ASX), PROTAGONIST THERAPEUTICS INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), RECRO PHARMA INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), LEE'S PHARM (HKEx), UNITY BIOTECHNOLOGY INC (NASDAQ), GERON CORP (NASDAQ), SERES THERAPEUTICS (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), COMPUGEN (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), TELIX PHARMACEUTIC (ASX), PIERIS PHARMACEUTICALS INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), CHIASMA INC (NASDAQ), DPHARMA (Bursa), KAMADA (NASDAQ), ARDELYX INC (NASDAQ), ATHERSYS INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), MANNKIND CORPORATION (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), 22ND CENTURY GROUP INC (NYSE American), AXCELLA HEALTH INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), AFFIMED N V (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), PFENEX INC (NYSE American), NOVAVAX INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), ENZO BIOCHEM INC (NYSE), XOMA CORP (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), GLYCOMIMETICS INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), CHIMERIX INC (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), LINEAGE CELL THERAPEUTICS INC (NYSE American), IMV INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), UNI-BIO GROUP (HKEx), ALDEYRA THERAPEUTICS (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), PALATIN TECHNOLOGIES INC (NYSE American), BIOXCEL THERAPEUTICS INC (NASDAQ), BBI LIFE SCI (HKEx), STANDARD DIVERSIFIED INC (NYSE American), PARATEK PHARMACEUTICALS INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), NANTKWEST INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), SESEN BIO INC (NASDAQ), CYNATA THERAPEUTICS LTD (ASX), TOCAGEN INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), ADURO BIOTECH INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), VERASTEM INC (NASDAQ), SYNLOGIC INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), SUNESIS PHARMACEUTICALS INC (NASDAQ), SAVARA INC (NASDAQ), EDAP TMS S.A. SPON ADS EACH REPR 1 ORD SHARE (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), TREVENA INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), PORT (SET), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), CEL-SCI CORP (NYSE American), NEON THERAPEUTICS INC (NASDAQ), VACCINEX INC (NASDAQ), IBIO INC (NYSE American), VTV THERAPEUTICS INC (NASDAQ), INFLARX N V (NASDAQ), ORGENESIS INC (NASDAQ), OTONOMY INC (NASDAQ), RESAPP HEALTH LIMITED (ASX), COHBAR INC (NASDAQ), EQUILLIUM INC (NASDAQ), ARAVIVE INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), CURIS INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), NEWLINK GENETICS CORP (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), INMUNE BIO INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), PHYLOGICA LIMITED (ASX), IMMUTEP LTD (ASX), HEMISPHERX BIOPHARMA INC (NYSE American), IMMUTEP LTD SPON ADR EACH REP 100 ORD SHS (NASDAQ), SYNTHETIC BIOLOGICS INC (NYSE American), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), IMUGENE LIMITED (ASX), VERMILLION INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), CT ENTERPRISE (HKEx), IVERIC BIO INC (NASDAQ), ARMATA PHARMACEUTICALS INC (NYSE American), REGENT PACIFIC (HKEx), FORWARD PHARMA AS SPON ADR EACH REP 2 ORD SHS (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), ORTHOCELL LIMITED (ASX), EVOGENE LTD (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), SENESTECH INC (NASDAQ), ZELDA THERAPEUTICS LTD (ASX), CELLDEX THERAPEUTICS INC (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), INDIA GLOBALIZATION CAPITAL INC (NYSE American), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), ZAFGEN INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), BIOCARDIA INC (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), CONTRAFECT CORP (NASDAQ), BIOTRON (ASX), SOPHIRIS BIO INC (NASDAQ), RHINOMED LIMITED (ASX), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), VISTAGEN THERAPEUTICS INC (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), EXTRAWELL PHAR (HKEx), BIOSINO BIO-TEC (HKEx), MICROBOT MEDICAL INC (NASDAQ), INVEX THERAPEUTICS LTD NPV (ASX), BIOCEPT INC (NASDAQ), SOLIGENIX INC (NASDAQ), MEMPHASYS LTD (ASX), CELLECTAR BIOSCIENCES INC (NASDAQ), ACTINIUM PHARMACEUTICALS INC (NYSE American), HISTOGENICS CORP (NASDAQ), VICAL INC (NASDAQ), ORAGENICS INC (NYSE American), CO DIAGNOSTICS INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), ISORAY INC (NYSE American), BIONANO GENOMICS INC (NASDAQ), FIBROCELL SCIENCE INC (NASDAQ), PRECIPIO INC (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), PATRYS LIMITED (ASX), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), ALTERITY THERAPEUTICS LIMITED (ASX), CLEVELAND BIOLABS INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), PROTEOMICS INTL LABORATORIES LTD (ASX), ACHIEVE LIFE SCIENCE INC (NASDAQ), KAZIA THERAPEUTICS LIMITED (ASX), NOVELION THERAPEUTICS INC (NASDAQ), NANOVIRICIDES INC (NYSE American), REGENEUS LTD (ASX), ANTEO DIAGNOSTICS LIMITED (ASX), TROVAGENE INC (NASDAQ), CONTANGO ASSET MANAGEMENT LIMITED (ASX), BIONOMICS LTD (ASX), ONCONOVA THERAPEUTICS INC (NASDAQ), ADALTA LTD (ASX), IMMURON LIMITED (ASX), DARE BIOSCIENCE INC (NASDAQ), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), CELLMID LIMITED (ASX), GENETIC TECHNOLOGIES (ASX), ATYR PHARMA INC (NASDAQ), GENERA BIOSYSTEMS LIMITED (ASX), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), MOTIF BIO PLC ADR EACH REPR 20 SHS SPON (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), PRESCIENT THERAPEUTICS LIMITED (ASX), VAXART INC (NASDAQ), NOVABAY PHARMACEUTICALS INC (NYSE American), CONATUS PHARMACEUTICALS INC (NASDAQ), HOLISTA COLLTECH LIMITED (ASX), CAPRICOR THERAPEUTICS INC (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), LIVING CELL TECHNOLOGIES (ASX), REXAHN PHARMACEUTICALS INC (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), HAO WEN HLDGS (HKEx), PHIO PHARMACEUTICALS CORP (NASDAQ), BENITEC BIOPHARMA LTD SPON ADR EA REPR 20 ORD (NASDAQ), BENITEC BIOPHARMA LTD (ASX), BIOXYNE LIMITED (ASX), CYCLACEL PHARMA IN (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), ANATARA LIFESCIENCES LTD (ASX), ARCA BIOPHARMA INC (NASDAQ), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), TRILLIUM THERAPEUTICS INC (NASDAQ), ADVAXIS INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), ACTINOGEN MEDICAL LTD (ASX), MGRC (Bursa), PROTEON THERAPEUTICS INC (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), MEGASUN (Bursa), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), AVECHO BIOTECHNOLOGY LTD (ASX), NANOLLOSE LTD (ASX), OPGEN INC (NASDAQ), CCP TECHNOLOGIES LTD (ASX), TBG DIAGNOSTICS LTD (ASX), NEURALSTEM INC (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADR EACH REP 20 ORD SHS (NASDAQ), NOVITA HEALTHCARE LTD (ASX), MEDIBIO LIMITED (ASX), FACTOR THERAPEUTICS LIMITED (ASX), AMPLIA THERAPEUTICS LTD (ASX), ALCHEMIA LIMITED (ASX), BPH ENERGY LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+0.035
+13.73 %
10 Days -+0.060
+26.09 %
20 Days -+0.060
+26.09 %
Medium Term Return 3 Months -+0.140
+93.33 %
6 Months -+0.170
+141.67 %
1 Year -+0.090
+45.00 %
Long Term Return 2 Years --0.030
-9.38 %
3 Years -+0.070
+31.82 %
5 Years -+0.005
+1.75 %
Annualised Return Annualised --
+0.35 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.100 - 0.290 Change From 1 Year Low +0.190 % Change From 1 Year Low (%) +190.00
Change From 1 Year High - % Change From 1 Year High (%) -
2 Years Range 0.100 - 0.325 Change From 2 Years Low +0.190 % Change From 2 Years Low (%) +190.00
Change From 2 Years High -0.035 % Change From 2 Years High (%) -10.77
5 Years Range 0.100 - 0.800 Change From 5 Years Low +0.190 % Change From 5 Years Low (%) +190.00
Change From 5 Years High -0.510 % Change From 5 Years High (%) -63.75
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

The Company was incorporated in Singapore on 22 September 2006 as a private limited company under the name Reyphon Agriceutical Pte Ltd. The Company was renamed to Reyphon Agriceutical Limited on 13 July 2007.
The Group's principal products are gibberellic acids, a plant growth regulator, and validamycin, a plant antibiotic. The Group also possess the know-how to produce fermentation-based pesticides. Its main product, gibberellic acids, is used in China mainly in the cultivation of hybrid rice, cotton, fruits and vegetables. Through active R&D, its objective is to widen the applications of gibberellic acids to cultivation of other plants such as tea plants, peanuts and soybean and lower its production costs and offer customers greater value with our gibberellic acids products.The Group manufactured, agriceutical products may be broadly classified into the following categories:-
(a) plant growth regulators;
(b) pesticides which include plant antibiotics, insecticide and weedicides; and
(c) fertilisers.

Its production facilities are located in Southern Industrial Development Zone of Xin?gan County, Jiangxi Province of China on a land area of approximately 65,002 sq m. Its products are sold throughout China such as Zhejiang, Fujian, Guangdong, Guangxi, Yunnan, Jiangsu, Shangdong, Hebei, Xinjiang, Anhui, Hainan, Hunan, Sichuan and Hubei. The Group also exports its products to countries such as United States, India, Turkey, Belgium, Canada, Germany, Malaysia, Pakistan, Spain, United Kingdom and Vietnam.

Change of Name:
Reyphon Agriceutical Limited to Suntar Eco-City Limited. Trading under the new name wef 14 June 2012.

Current core business of the Group has hereby expanded to include the eco-tourism real estate development and management business.

IPO Performance

Listing Date 01 Aug 2007 Full Subscription Rate (x) 13.55
No of Placement Shares (M) 76.60 No of Public Offer Shares (M) 2.00 Public Offer Subscription Rate (x) 494.05
IPO Price (SGD) a 1.950 First Day Close (SGD) a 3.050 First Week Close (SGD) a 2.500
Current vs IPO Price (%) -85.13 First Day Gain (%) +56.41 First Week Gain (%) +28.21
Notes:
  1. Adjusted for the following: Share Consolidation 1 for 5 on 19/11/2015

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2018 Dec 2018 Part 1(3.17 MB)
Annual Report 2017 Dec 2017 Part 1(4.01 MB)
Annual Report 2016 Dec 2016 Part 1(1.06 MB)
Annual Report 2015 Dec 2015 Part 1(1.97 MB)
Annual Report 2014 Dec 2014 Part 1(1.50 MB)
Annual Report 2013 Dec 2013 Part 1(0.95 MB)
Annual Report 2012 Dec 2012 Part 1(0.51 MB)
Annual Report 2011 Dec 2011 Part 1(0.64 MB)
Annual Report 2010 Dec 2010 Part 1(0.85 MB)
Annual Report 2009 Dec 2009 Part 1(0.98 MB)
Annual Report 2008 Dec 2008 Part 1(1.53 MB)
Annual Report 2007 Dec 2007 Part 1(1.61 MB)
IPO Prospectus
IPO Prospectus 2007 Jul 2007 Part 1(3.22 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
21 Aug 2019 0.290 0.290 0.290 0.290 10,000 0.2900
20 Aug 2019 0.290 0.290 0.290 0.290 10,000 0.2900
19 Aug 2019 0.260 0.260 0.260 0.260 - -
16 Aug 2019 0.260 0.260 0.260 0.260 10,000 0.2600
15 Aug 2019 0.255 0.255 0.255 0.255 - -
14 Aug 2019 0.200 0.255 0.200 0.255 13,800 0.2518
13 Aug 2019 0.250 0.255 0.250 0.255 37,200 0.2516
08 Aug 2019 0.230 0.230 0.230 0.230 - -
07 Aug 2019 0.230 0.230 0.230 0.230 - -
06 Aug 2019 0.230 0.230 0.230 0.230 - -
05 Aug 2019 0.230 0.230 0.230 0.230 - -
02 Aug 2019 0.230 0.230 0.230 0.230 - -
01 Aug 2019 0.230 0.230 0.230 0.230 - -
31 Jul 2019 0.230 0.230 0.230 0.230 - -
30 Jul 2019 0.230 0.230 0.230 0.230 8,000 0.2300
29 Jul 2019 0.230 0.230 0.230 0.230 - -
26 Jul 2019 0.230 0.230 0.230 0.230 - -
25 Jul 2019 0.230 0.230 0.230 0.230 - -
24 Jul 2019 0.230 0.230 0.230 0.230 21,000 0.2300
23 Jul 2019 0.230 0.230 0.230 0.230 14,000 0.2300
22 Jul 2019 0.230 0.230 0.230 0.230 - -
19 Jul 2019 0.230 0.230 0.230 0.230 - -
Summary
Current 2 Weeks
(06 Aug 2019 to 21 Aug 2019)
0.230 0.290 0.200 0.290 81,000 -
Previous 2 Weeks
(23 Jul 2019 to 05 Aug 2019)
0.230 0.290 0.200 0.230 43,000 -
4 Weeks from
(25 Jun 2019 to 22 Jul 2019)
0.165 0.290 0.165 0.230 51,200 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.